Clinical Trial Update: Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia [Phase 3]

View source ↗

Summary

Phase 3 study of Trimodulin (BT588) for community-acquired pneumonia including COVID-19 pneumonia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia
• Pneumonia
• Respiratory Distress Syndrome

Drugs mentioned

• Trimodulin (BT588)

Snippet

Sponsor: Biotest | Conditions: Respiratory Infection, Pneumonia | Phase 3 | Status: TERMINATED